Phase II Study of the AKT inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed on Erlotinib

PURPOSE: Preclinical modeling in non-small cell lung cancer (NSCLC) showed that stimulation with hepatocyte growth factor (HGF), the ligand for MET, could reverse the cytostatic and cytotoxic effects of the epidermal-growth factor receptor (EGFR) inhibitor erlotinib in erlotinib-sensitive cell lines...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lara, Primo N., Longmate, Jeff, Mack, Philip C., Kelly, Karen, Socinski, Mark A., Salgia, Ravi, Gitlitz, Barbara, Li, Tianhong, Koczywas, Mariana, Reckamp, Karen L., Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4592395/
https://ncbi.nlm.nih.gov/pubmed/26106072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3281
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados